免疫介导性皮肤病靶向治疗随机对照试验中退出者报告情况:基于系统评价的横断面研究
结果显示26%的试验在退出总人数上存在差异,仅33%的试验在退出人数和原因上完全一致,且多数退出原因无法充分分类,提示报告存在显著缺陷。
要点
- 论文与注册库之间退出人数不一致的试验占26%。
- 仅33%的试验在退出人数和原因上完全一致。
- 多数退出原因缺乏足够信息,无法标准化分类。
核心结论
- 评估慢性炎症性皮肤病靶向治疗的随机对照试验在退出参与者报告方面存在显著缺陷。
- 缺陷表现为数据不完整、来源间不一致以及缺乏标准化术语。
研究设计与样本
- 横断面研究,纳入来自四项系统评价的随机对照试验,评估斑块状银屑病、化脓性汗腺炎、特应性皮炎或斑秃成人患者的靶向治疗。
- 主要结局为论文与试验注册库之间退出参与者总数及每个治疗组退出人数存在至少一处差异的试验比例。
主要发现
- 在96/209项报告主要终点退出参与者数据的随机对照试验中,25项(26%)在来源间退出总人数存在差异。
- 在退出人数相同的71项试验中,5项未报告原因,34项报告的原因数量或原因不同。
- 总体仅32/96项试验(33%)在退出人数和原因上完全一致。
- 论文和注册库分别报告73种和59种不同退出原因,其中70%(51/73)和68%(40/59)信息不足无法分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess both in publications and trial registries the reporting of reasons of participant withdrawals in randomized controlled trials (RCTs) evaluating targeted therapies for chronic inflammatory skin diseases, to evaluate the discrepancies between these sources and to classify the reported reasons for withdrawal. STUDY DESIGN AND SETTING: We included RCTs published between September 27, 2009, and October 1, 2024, from four systematic reviews assessing the efficacy or safety of targeted therapies in adult patients with plaque psoriasis, hidradenitis suppurativa, atopic dermatitis, or alopecia areata. The main outcome was the proportion of RCTs presenting at least one discrepancy in the number of withdrawn participants (WPs) in total and per treatment arm between the published article and the trial registry. For trials reporting the same number of WP in both sources, we also evaluated discrepancies in reasons for withdrawal. We classified the reasons for withdrawal (eg, inefficacy and adverse events) and the mechanism (eg, missing at random and missing not at random). RESULTS: Among the 96/209 included RCTs reporting WP data for the primary end point in both sources, 25 (26%) had discrepancies between sources in total WP number. Then, among the 71 with the same WP number, 5 did not report reasons and 34 report a different number and/or reasons between sources. Thus, overall, 32/96 trials (33%) were fully concordant for both WP numbers and reasons. Among the 73 and 59 different reasons reported in publications and trial registries respectively, 70% (51/73) and 68% (40/59) were not informative enough to be classified. CONCLUSION: Our study revealed significant shortcomings in the reporting of participant withdrawals, marked by incomplete data, discrepancies between sources, and a lack of standardized terminology in RCTs evaluating systemic targeted therapies for chronic inflammatory skin diseases.
引用
- Kottler D, Guelimi R, Afach S, et al. Reporting of withdrawn participants in randomized controlled trials assessing targeted therapies in immune-mediated skin diseases: a cross-sectional study of trials from systematic reviews. J Clin Epidemiol. 2026. PMID: 41997220. doi:10.1016/j.jclinepi.2026.112273
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。